The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets-Reference-Cited by-同舟云学术

The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets

Published:2022-04-28 Issue:7 Volume:38 Page:1167-1176
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Butzkueven Helmut¹²,Moore Nicholas³,Aydemir Aida⁴,Sõnajalg Jaak⁵,Bezemer Irene⁶,Korhonen Pasi⁷,Sabidó Meritxell⁸,

Affiliation:

1. Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia

2. The Alfred Hospital, Melbourne, Australia

3. Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France

4. Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA)

5. Global Database Studies, IQVIA, Tartu, Estonia

6. Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands

7. IQVIA (former EPID Research), Espoo, Finland

8. Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2059977

Reference31 articles.

1. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

2. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

3. An update on the safety of treating relapsing-remitting multiple sclerosis

4. European Medicines Agency. Use of disease registries for benefit-risk evaluation of medicines: a regulatory perspective 2018. Available from: www.ema.europa.eu/en/documents/presentation/presentation-registry-initiative-april-2018_en.pdf.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals;Neurology and Therapy;2024-05-17

2. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis;Current Medical Research and Opinion;2023-09-19

3. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study;Multiple Sclerosis and Related Disorders;2023-08

4. Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis;Neurology and Therapy;2023-06-29

5. Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan: Fiscal Years 2011–2020;Viruses;2023-04-14